Buchumschlag

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at lea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Cross, Nicholas C. P. (VerfasserIn) , Müller, Martin Christian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 05 February 2015
In: Leukemia
Year: 2015, Jahrgang: 29, Heft: 5, Pages: 999-1003
ISSN:1476-5551
DOI:10.1038/leu.2015.29
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1038/leu.2015.29
Verlag, Volltext: https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu201529
Volltext
Verfasserangaben:N.C.P. Cross, H.E. White, D. Colomer, H. Ehrencrona, L. Foroni, E. Gottardi, T. Lange, T. Lion, K. Machova Polakova, S. Dulucq, G. Martinelli, E. Oppliger Leibundgut, N. Pallisgaard, G. Barbany, T. Sacha, R. Talmaci, B. Izzo, G. Saglio, F. Pane, M.C. Müller and A. Hochhaus
Beschreibung
Zusammenfassung:Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Beschreibung:Gesehen am 29.11.2017
Beschreibung:Online Resource
ISSN:1476-5551
DOI:10.1038/leu.2015.29

Ähnliche Einträge